Phase I Study of Everolimus + Bendamustine in Patients With Relapsed/Refractory Hematological Malignancies
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary) ; Bendamustine
- Indications Haematological malignancies
- Focus Adverse reactions
- 02 Jan 2019 Status changed from active, no longer recruiting to completed.
- 27 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Jan 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.